Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus salivarius
- Development stage
- Phase 2
- Lead developer
- BLIS Technologies
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Streptococcus salivarius is a species of spherical, gram-positive, facultative anaerobic lactic acid bacteria that is both catalase and oxidase negative. It is one of the first colonizers of the human oral cavity and gut after birth. Certain strains, particularly K12 and M18, are used as probiotics to prevent oral infections and support immune function. These strains produce bacteriocin-like inhibitory substances (BLIS) including lantibiotics such as Salivaricin A2 and Salivaricin B, which inhibit the growth of pathogenic bacteria like Streptococcus pyogenes (which causes strep throat), Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. S. salivarius probiotics are typically administered as lozenges, chewable tablets, or oral powders to promote colonization of the oral cavity and upper respiratory tract.
- Brand names
- Bactoblis
- Other names
- S. salivariusS. salivarius K12S. salivarius M18S. salivarius 24SMB
02
Targets
NF-κB
Beyond the preview
Go deeper on Streptococcus salivarius.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus salivarius.